The review — which didn't involve tirzepatide as Component of the Evaluation — was framed to be a counterpoint to a different analyze that located that GLP-1 agonists increased the risk for pancreatitis.2). Tirzepatide’s capacity to co-administer GIP and GLP-1 has synergistic results on lessening overall body bodyweight, foods usage, and Body